Case Reports Open access

Polymyositis following varicella and mumps infection in adults: report of two cases

Authors

Published
19 December 2023
Section
Case Reports
DOI
10.4081/reumatismo.2023.1562

Abstract

Idiopathic immune myopathies (IIMs) are autoimmune diseases caused by immune-mediated muscle damage. The etiology remains unclear. Epidemiological and experimental studies, both in animals and humans, hint at viruses as major environmental factors able to trigger aberrant immune responses through many different mechanisms. However, only a few cases of either dermatomyositis or polymyositis following a specific viral infection have been reported in the literature. The objective of this study is to describe the clinical features and the treatment strategy of 2 cases of polymyositis developing shortly after chickenpox and mumps, respectively, and to review the existing literature on the topic. The clinical records of the 2 patients suspected to have developed inflammatory myositis following a viral infection were reviewed. Their clinical history, main laboratory findings, and treatment outcome are presented here. Moreover, a literature search was performed in the PubMed and MEDLINE databases to identify reports describing the association between viral infections and IIMs in patients aged ≥18. The 2 patients reported here developed polymyositis shortly after chickenpox and mumps, respectively, suggesting a causal role for viruses in triggering autoimmunity. Only a few reports published between 1990 and 2020 were found in the literature, possibly linking infections to myositis development. Intravenous immunoglobulin and rituximab were effective for the treatment of viral-triggered polymyositis.

Keywords

References

  1. Baig S, Paik JJ. Inflammatory muscle disease - an update. Best Pract Res Clin Rheumatol 2020; 34: 101484. DOI: https://doi.org/10.1016/j.berh.2019.101484
  2. Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses 2019; 11: 762. DOI: https://doi.org/10.3390/v11080762
  3. Chou JW, Lin YL, Cheng KS, Wu PY, Ju TR. Dermatomyositis induced by hepatitis B virus-related hepatocellular carcinoma: a case report and review of the literature. Intern Med 2017; 56: 1831‐7. DOI: https://doi.org/10.2169/internalmedicine.56.7595
  4. Carroll MB, Holmes R. Dermatomyositis and HIV infection: case report and review of the literature. Rheumatol Int 2011; 31: 673‐9. DOI: https://doi.org/10.1007/s00296-009-1231-x
  5. Zampieri S, Ghirardello A, Iaccarino L, Briani C, Sarzi-Puttini P, Atzeni F, et al. Polymyositis-dermatomyositis and infections. Autoimmunity 2006; 39: 191‐6. DOI: https://doi.org/10.1080/08916930600622348
  6. Cuomo G, Iagnocco A. Manuale di reumatologia. Turin: Minerva Med, 2022. [Book in Italian].
  7. Ytterberg SR. Infectious agents associated with myopathies. Curr Opin Rheumatol 1996; 8: 507-13. DOI: https://doi.org/10.1097/00002281-199611000-00003
  8. Bowles NE, Dubowitz V, Sewry CA, Archard LC. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1987; 1: 1004-7. DOI: https://doi.org/10.1016/S0140-6736(87)92271-9
  9. Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology 2000; 39: 1037-9. DOI: https://doi.org/10.1093/rheumatology/39.9.1037
  10. Fox SA, Ward BK, Robbins PD, Mastaglia FL, Swanson NR. Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction. Muscle Nerve 1996; 19: 23-8. DOI: https://doi.org/10.1002/(SICI)1097-4598(199601)19:1<23::AID-MUS4>3.0.CO;2-A
  11. Leclair V, Lundberg IE. New myositis classification criteria-what we have learned since Bohan and Peter. Curr Rheumatol Rep 2018; 20: 18. DOI: https://doi.org/10.1007/s11926-018-0726-4
  12. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955‐64. DOI: https://doi.org/10.1136/annrheumdis-2017-212786
  13. Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 2018; 28: 913‐21. DOI: https://doi.org/10.1080/14397595.2018.1467257
  14. Baccaro ACCD, Behrens Pinto GL, Carboni RCS, Shinjo SK. The clinical manifestations at the onset of antisynthetase syndrome: a chameleon with multiple faces. Reumatismo 2020; 72: 86-92. DOI: https://doi.org/10.4081/reumatismo.2020.1275
  15. Goswami RP, Haldar SN, Chatterjee M, Vij P, van der Kooi AJ, Lim J, et al. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis. Autoimmun Rev 2022; 21: 102997. DOI: https://doi.org/10.1016/j.autrev.2021.102997
  16. Barsotti S, Cioffi E, Tripoli A, Tavoni A, D’Ascanio A, Mosca M, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo 2018; 70: 78-84. DOI: https://doi.org/10.4081/reumatismo.2018.1011

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2023 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.